Search

Your search keyword '"Rasmussen, M"' showing total 3,266 results
Start Over Author "Rasmussen, M"
3,266 results on '"Rasmussen, M"'

1. Persistence of Minimal Invariant Sets for Certain Set-Valued Dynamical Systems: A Boundary Mapping Approach

Author

Kourliouros, K., Lamb, J. S. W., Rasmussen, M., Tey, W. H., Timperi, K. G., and Turaev, D.

Subjects
Mathematics - Dynamical Systems, 37H30, 37C05, 37D05, 37G35, 53D10
Abstract

We study the problem of persistence of minimal invariant sets with smooth boundary for a certain class of discrete-time set-valued dynamical systems, naturally arising in the context of random dynamical systems with bounded noise. In particular, we introduce a single-valued map, the so-called boundary map, which has the property that a certain class of invariant submanifolds for this map is in one-to-one correspondence with invariant sets for the corresponding set-valued map. We show that minimal invariant sets with smooth boundary persist under small perturbations of the set-valued map, provided that the associated boundary map is normally hyperbolic at the unit normal bundle of the boundary.

Published
2023

2. An Improved Method for Coupling Hydrodynamics with Astrophysical Reaction Networks

Author

Zingale, M., Katz, M. P., Nonaka, A., and Rasmussen, M.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics, Nuclear Theory
Abstract

Reacting astrophysical flows can be challenging to model because of the difficulty in accurately coupling hydrodynamics and reactions. This can be particularly acute during explosive burning or at high temperatures where nuclear statistical equilibrium is established. We develop a new approach based on the ideas of spectral deferred corrections (SDC) coupling of explicit hydrodynamics and stiff reaction sources as an alternative to operator splitting that is simpler than the more comprehensive SDC approach we demonstrated previously. We apply the new method to a double detonation problem with a moderately-sized astrophysical nuclear reaction network and explore the timestep size and reaction network tolerances to show that the simplified-SDC approach provides improved coupling with decreased computational expense compared to traditional Strang operator splitting. This is all done in the framework of the Castro hydrodynamics code, and all algorithm implementations are freely available., Comment: accepted to ApJ. Castro is available at https://github.com/amrex-astro/Castro -- all code for the results here is in the github repo

Published
2022
Full Text
View/download PDF

3. An Improved Method for Coupling Hydrodynamics with Astrophysical Reaction Networks

Author

Zingale, M, Katz, MP, Nonaka, A, and Rasmussen, M

Subjects
Astronomical and Space Sciences, Atomic, Molecular, Nuclear, Particle and Plasma Physics, Physical Chemistry (incl. Structural), Astronomy & Astrophysics
Abstract

Reacting astrophysical flows can be challenging to model, because of the difficulty in accurately coupling hydrodynamics and reactions. This can be particularly acute during explosive burning or at high temperatures where nuclear statistical equilibrium is established. We develop a new approach, based on the ideas of spectral deferred corrections (SDC) coupling of explicit hydrodynamics and stiff reaction sources as an alternative to operator splitting, that is simpler than the more comprehensive SDC approach we demonstrated previously. We apply the new method to a double-detonation problem with a moderately sized astrophysical nuclear reaction network and explore the time step size and reaction network tolerances, to show that the simplified-SDC approach provides improved coupling with decreased computational expense compared to traditional Strang operator splitting. This is all done in the framework of the Castro hydrodynamics code, and all algorithm implementations are freely available.

Published
2022

5. Ion Impact Induced Ultrafast Electron Dynamics in Correlated Materials and Finite Graphene Clusters

Author

Bonitz, M., Balzer, K., Schlünzen, N., Rasmussen, M., and Joost, J. -P.

Subjects
Condensed Matter - Strongly Correlated Electrons, Physics - Plasma Physics
Abstract

Strongly correlated systems of fermions have an interesting phase diagram arising from the Hubbard gap. Excitation across the gap leads to the formation of doubly occupied lattice sites (doublons). This state offers interesting electronic and optical properties. Moreover, when the system is driven out of equilibrium interesting collective dynamics may arise that are related to the spatial propagation of doublons. Here, a novel mechanism that was recently proposed by us [Balzer \textit{et al.}, submitted for publication] is verified by exact diagonalization and nonequilibrium Green functions (NEGF) simulations---fermionic doublon creation by the impact of energetic ions. We report the formation of a nonequilibrium steady state with homogeneous doublon distribution. A physically intuitive picture is given in terms of an analytical model for a two-site system where the doublon formation is explained in terms of a two-fold passage of an avoided crossing (Landau-Zener picture). The effect should be particularly important for strongly correlated finite systems, such as graphene nanoribbons, and directly observable with fermionic atoms in optical lattices. We demonstrate that doublon formation and propagation in correlated lattice systems can be accurately simulated with NEGF. In addition to two-time results we present single-time results within the generalized Kadanoff-Baym ansatz (GKBA) with Hartree-Fock propagators (HF-GKBA), and we present systematic improvements that use correlated propagators (correlated GKBA).

Published
2018
Full Text
View/download PDF

7. Quadruplet pregnancy outcome with and without fetal reduction: Danish national cohort study (2008–2018) and comparison with dichorionic twins

Author

Rasmussen, M. K., primary, Kristensen, S. E., additional, Ekelund, C. K., additional, Sandager, P., additional, Jørgensen, F. S., additional, Hoseth, E., additional, Sperling, L., additional, Zingenberg, H. J., additional, Hjortshøj, T. D., additional, Gadsbøll, K., additional, Wright, A., additional, Wright, D., additional, McLennan, A., additional, Sundberg, K., additional, and Petersen, O. B., additional

Published
2024
Full Text
View/download PDF

12. Quadruplet pregnancy outcome with and without fetal reduction:Danish national cohort study (2008–2018) and comparison with dichorionic twins

Author

Rasmussen, M. K., Kristensen, S. E., Ekelund, C. K., Sandager, P., Jørgensen, F. S., Hoseth, E., Sperling, L., Zingenberg, H. J., Hjortshøj, T. D., Gadsbøll, K., Wright, A., Wright, D., McLennan, A., Sundberg, K., Petersen, O. B., Rasmussen, M. K., Kristensen, S. E., Ekelund, C. K., Sandager, P., Jørgensen, F. S., Hoseth, E., Sperling, L., Zingenberg, H. J., Hjortshøj, T. D., Gadsbøll, K., Wright, A., Wright, D., McLennan, A., Sundberg, K., and Petersen, O. B.

Abstract

Objectives To perform a nationwide study of quadrichorionic quadriamniotic (QCQA) quadruplet pregnancies and to compare the pregnancy outcome in those undergoing fetal reduction with non-reduced quadruplets and dichorionic diamniotic (DCDA) twin pregnancies from the same time period. Methods This was a retrospective Danish national register-based study performed using data from the national Danish Fetal Medicine Database, which included all QCQA quadruplets and all non-reduced DCDA twin pregnancies with an estimated due date between 2008 and 2018. The primary outcome measure was a composite of adverse pregnancy outcomes, including pregnancy loss or intrauterine death of one or more fetuses. Secondary outcomes included gestational age at delivery, the number of liveborn children, preterm delivery before 28, 32 and 37 gestational weeks and birth weight. Data on pregnancy complications and baseline characteristics were also recorded. Outcomes were compared between reduced and non-reduced quadruplet pregnancies, and between DCDA pregnancies and quadruplet pregnancies reduced to twins. A systematic literature search was performed to describe and compare previous results with our findings. Results Included in the study were 33 QCQA quadruplet pregnancies, including three (9.1%) non-reduced pregnancies, 28 (84.8%) that were reduced to twin pregnancy and fewer than three (6.1%) that were reduced to singleton pregnancy, as well as 9563 DCDA twin pregnancies. Overall, the rate of adverse pregnancy outcome was highest in non-reduced quadruplets (66.7%); it was 50% in quadruplets reduced to singletons and 10.7% in quadruplets reduced to twins. The proportion of liveborn infants overall was 91.1% of the total number expected to be liveborn in quadruplet pregnancies reduced to twins. This was statistically significantly different from 97.6% in non-reduced dichorionic twins (P = 0.004), and considerably higher than 58.3% in non-reduced quadruplets. Th, Objectives: To perform a nationwide study of quadrichorionic quadriamniotic (QCQA) quadruplet pregnancies and to compare the pregnancy outcome in those undergoing fetal reduction with non-reduced quadruplets and dichorionic diamniotic (DCDA) twin pregnancies from the same time period. Methods: This was a retrospective Danish national register-based study performed using data from the national Danish Fetal Medicine Database, which included all QCQA quadruplets and all non-reduced DCDA twin pregnancies with an estimated due date between 2008 and 2018. The primary outcome measure was a composite of adverse pregnancy outcomes, including pregnancy loss or intrauterine death of one or more fetuses. Secondary outcomes included gestational age at delivery, the number of liveborn children, preterm delivery before 28, 32 and 37 gestational weeks and birth weight. Data on pregnancy complications and baseline characteristics were also recorded. Outcomes were compared between reduced and non-reduced quadruplet pregnancies, and between DCDA pregnancies and quadruplet pregnancies reduced to twins. A systematic literature search was performed to describe and compare previous results with our findings. Results: Included in the study were 33 QCQA quadruplet pregnancies, including three (9.1%) non-reduced pregnancies, 28 (84.8%) that were reduced to twin pregnancy and fewer than three (6.1%) that were reduced to singleton pregnancy, as well as 9563 DCDA twin pregnancies. Overall, the rate of adverse pregnancy outcome was highest in non-reduced quadruplets (66.7%); it was 50% in quadruplets reduced to singletons and 10.7% in quadruplets reduced to twins. The proportion of liveborn infants overall was 91.1% of the total number expected to be liveborn in quadruplet pregnancies reduced to twins. This was statistically significantly different from 97.6% in non-reduced dichorionic twins (P = 0.004), and considerably higher than 58.3% in non-reduced quadruplets. The rates of preterm deliv

Published
2024

13. Drug survival of biologic therapies for palmoplantar pustulosis:A nationwide study

Author

Bertelsen, T., Egeberg, A., Skov, L., Rasmussen, M., Bryld, L., Funding, A., Ajgeiy, K., Thein, D., Bertelsen, T., Egeberg, A., Skov, L., Rasmussen, M., Bryld, L., Funding, A., Ajgeiy, K., and Thein, D.

Abstract

Background Biological therapies have established efficacy in psoriasis vulgaris. However, palmoplantar pustulosis (PPP) has proven difficult to treat, and data on drug survival in these patients remain scarce. Objective To investigate drug survival of biological treatments in a nationwide cohort of patients with PPP. Methods We included all patients treated for PPP with a biologic from a prospective Danish nationwide registry between 2007 and 2019. Descriptive statistics were reported. Drug survival was calculated for all patients and specified for the most frequently used biologics. Drug survival was reported as median time to discontinuation. Kaplan–Meier plots were used to visualize drug survival. Trajectories of Dermatology Life Quality Index (DLQI) scores were plotted by interpolating between the different visits with a dermatologist for each treatment course. Results We identified 85 individual patients who received biological therapy for PPP across 194 treatment courses during follow-up. Of the included treatment courses, 151 (77.8%) were discontinued. The most frequent cause of discontinuation was ineffective response to treatment (54.3%), while 18.5% of courses were discontinued due to adverse events. The median drug survival across all therapies for PPP was 9.3 (Inter quartile range (IQR), 3.9–25.6) months. Ustekinumab demonstrated the longest median time to discontinuation of 14.6 (IQR, 9.1–51.8) months. The proportion of bio-naive patients in treatment at 12 months were according to drug 47.9% for adalimumab, 64.3% for ustekinumab and 40.0% for secukinumab. For bio-experienced, it was 58.2% adalimumab, 54.5% for ustekinumab and 51.4% for secukinumab. Conclusions The treatment of PPP poses significant challenges, with limited drug survival observed across all therapies regardless of prior experience with biologics. Ustekinumab demonstrated the longest median drug survival. Notably, patients discontin, Background: Biological therapies have established efficacy in psoriasis vulgaris. However, palmoplantar pustulosis (PPP) has proven difficult to treat, and data on drug survival in these patients remain scarce. Objective: To investigate drug survival of biological treatments in a nationwide cohort of patients with PPP. Methods: We included all patients treated for PPP with a biologic from a prospective Danish nationwide registry between 2007 and 2019. Descriptive statistics were reported. Drug survival was calculated for all patients and specified for the most frequently used biologics. Drug survival was reported as median time to discontinuation. Kaplan–Meier plots were used to visualize drug survival. Trajectories of Dermatology Life Quality Index (DLQI) scores were plotted by interpolating between the different visits with a dermatologist for each treatment course. Results: We identified 85 individual patients who received biological therapy for PPP across 194 treatment courses during follow-up. Of the included treatment courses, 151 (77.8%) were discontinued. The most frequent cause of discontinuation was ineffective response to treatment (54.3%), while 18.5% of courses were discontinued due to adverse events. The median drug survival across all therapies for PPP was 9.3 (Inter quartile range (IQR), 3.9–25.6) months. Ustekinumab demonstrated the longest median time to discontinuation of 14.6 (IQR, 9.1–51.8) months. The proportion of bio-naive patients in treatment at 12 months were according to drug 47.9% for adalimumab, 64.3% for ustekinumab and 40.0% for secukinumab. For bio-experienced, it was 58.2% adalimumab, 54.5% for ustekinumab and 51.4% for secukinumab. Conclusions: The treatment of PPP poses significant challenges, with limited drug survival observed across all therapies regardless of prior experience with biologics. Ustekinumab demonstrated the longest median drug survival. Notably, patients discontinuing therapy due to inefficacy exhibited higher

Published
2024

14. Treatment of patients with screen-detected colorectal cancer is less strenuous:a nationwide cohort study with long-term follow-up

Author

Dressler, J., Njor, S. H., Rasmussen, M., Jørgensen, L. N., Dressler, J., Njor, S. H., Rasmussen, M., and Jørgensen, L. N.

Abstract

Objective During the last two decades, organised colorectal cancer (CRC) screening has been widely implemented. It remains to be established if screen-detected CRC (SD-CRC) is associated with reduced long-term requirements for treatment as compared with patients with non-screen-detected CRC (NSD-CRC). Study design and methods This nationwide cohort study evaluated differences in treatment and healthcare contacts from the date of diagnosis to two years after comparing patients with SD-CRC and NSD-CRC. Data were collected from national healthcare registers, including patients aged 50–75 years and diagnosed with CRC between January 1st 2014 and March 31st 2018. Analyses were stratified into UICC stages and adjusted for sex, 5-year age groups, type of cancer (colonic/rectal), and Charlson comorbidity index score to address healthy user bias. Results In total, 12,040 patients were included, 4708 with SD-CRC and 7332 with NSD-CRC. In patients with SD-CRC, the duration of hospitalisation and rate of emergency surgery were reduced by 38 % (relative risk [RR] = 0.62) and 66 % (RR = 0.34), respectively. Moreover, this group was characterised by a 75 % reduction in oncological outpatient visits (RR = 0.35) and a reduced number of treatments with chemotherapy (RR = 0.57) and radiotherapy (RR = 0.50). There were no significant differences between the two populations in the rates of metastasectomy and the number of contacts with primary healthcare providers. Conclusion Compared to patients with NSD-CRC, patients with SD-CRC experience less hospitalisation and treatment within the first two years after diagnosis., Objective: During the last two decades, organised colorectal cancer (CRC) screening has been widely implemented. It remains to be established if screen-detected CRC (SD-CRC) is associated with reduced long-term requirements for treatment as compared with patients with non-screen-detected CRC (NSD-CRC). Study design and methods: This nationwide cohort study evaluated differences in treatment and healthcare contacts from the date of diagnosis to two years after comparing patients with SD-CRC and NSD-CRC. Data were collected from national healthcare registers, including patients aged 50–75 years and diagnosed with CRC between January 1st 2014 and March 31st 2018. Analyses were stratified into UICC stages and adjusted for sex, 5-year age groups, type of cancer (colonic/rectal), and Charlson comorbidity index score to address healthy user bias. Results: In total, 12,040 patients were included, 4708 with SD-CRC and 7332 with NSD-CRC. In patients with SD-CRC, the duration of hospitalisation and rate of emergency surgery were reduced by 38 % (relative risk [RR] = 0.62) and 66 % (RR = 0.34), respectively. Moreover, this group was characterised by a 75 % reduction in oncological outpatient visits (RR = 0.35) and a reduced number of treatments with chemotherapy (RR = 0.57) and radiotherapy (RR = 0.50). There were no significant differences between the two populations in the rates of metastasectomy and the number of contacts with primary healthcare providers. Conclusion: Compared to patients with NSD-CRC, patients with SD-CRC experience less hospitalisation and treatment within the first two years after diagnosis.

Published
2024

15. Local Spectral Deformation

Author

Engelmann, M., Møller, J. S., and Rasmussen, M. G.

Subjects
Mathematical Physics, Mathematics - Spectral Theory
Abstract

We develop an analytic perturbation theory for eigenvalues with finite multiplicities, embedded into the essential spectrum of a self-adjoint operator $H$. We assume the existence of another self-adjoint operator $A$ for which the family $H_\theta = e^{\mathrm{i}\theta A} H e^{-\mathrm{i}\theta A}$ extends analytically from the real line to a strip in the complex plane. Assuming a Mourre estimate holds for $\mathrm{i}[H,A]$ in the vicinity of the eigenvalue, we prove that the essential spectrum is locally deformed away from the eigenvalue, leaving it isolated and thus permitting an application of Kato's analytic perturbation theory.

Published
2015

20. Multi-unit dynamic PRA

Author

Mandelli, D., Parisi, C., Alfonsi, A., Maljovec, D., Boring, R., Ewing, S., St Germain, S., Smith, C., Rabiti, C., and Rasmussen, M.

Published
2019
Full Text
View/download PDF

21. The impact of knee instability with and without buckling on balance confidence, fear of falling and physical function: the Multicenter Osteoarthritis Study

Author

Nguyen, U-SDT, Felson, DT, Niu, J, White, DK, Segal, NA, Lewis, CE, Rasmussen, M, and Nevitt, MC

Subjects
Chronic Pain, Arthritis, Behavioral and Social Science, Aging, Clinical Research, Pain Research, Musculoskeletal, Accidental Falls, Activities of Daily Living, Aged, Cross-Sectional Studies, Disability Evaluation, Fear, Female, Humans, Joint Instability, Knee Joint, Male, Middle Aged, Osteoarthritis, Knee, Prevalence, Risk Factors, Weight-Bearing, Osteoarthritis, Epidemiology, Outcome measures, Falls, Biomedical Engineering, Clinical Sciences, Human Movement and Sports Sciences, Arthritis & Rheumatology
Abstract

ObjectiveKnee buckling, in which a knee gives way during weight-bearing, is common in people with knee pain and knee osteoarthritis (OA), but little is known about the prevalence of sensations of knee instability, slipping or shifting in which the knee does not actually buckle, or of the psychosocial and physical consequences of these symptoms.DesignWe asked participants in the Multicenter Osteoarthritis Study (MOST) separately about episodes of knee buckling and sensations of knee instability without buckling in the past 3 months, and assessed fear of falling, poor balance confidence (Activities-specific Balance Confidence (ABC) Scale ≤ 67/100), activity limitation due to concern about buckling, and poor physical function (Western Ontario and McMaster Universities Arthritis Index (WOMAC) physical function ≥ 28/68). We used Poisson regression to estimate prevalence ratios (PRs) for cross-sectional associations of buckling and sensations of instability without buckling with these outcomes, adjusting for confounders.ResultsOf 2120 participants (60% female, 40% ≥ 65 years, mean Body mass index (BMI): 31 kg/m258), 18% reported buckling, 27% had sensations of knee instability without buckling, and 9% reported both symptoms. Buckling and sensations of instability without buckling were each significantly associated with fear of falling, poor balance confidence, activity limitations, and poor WOMAC physical function. Subjects who reported both buckling and instability without buckling and those with at least two buckling episodes (15%) had the strongest association with poor outcomes.ConclusionsKnee buckling and especially sensations of knee instability without buckling were common and each was significantly associated with fear of falling, poor balance confidence, activity limitations, and poor physical function.

Published
2014

24. OP11.02: Pregnancy outcome of quadruplet pregnancies: a national Danish cohort study between 2008–2018

Author

Rasmussen, M. K., primary, Kristensen, S. E., additional, Ekelund, C. K., additional, Sandager, P., additional, Joergensen, F. S., additional, Hoseth, E., additional, Sperling, L., additional, Zingenberg, H. J., additional, Hjortshøj, T. D., additional, Gadsbøll, K. Mørch, additional, Wright, A., additional, Wright, D., additional, McLennan, A., additional, Sundberg, K., additional, and Petersen, O. B., additional

Published
2023
Full Text
View/download PDF

28. Rotation of stars in NGC 6134: a comparison of Delta Scuti stars and non-variable stars

Author

Rasmussen, M. B., Bruntt, H., Frandsen, S., Paunzen, E., and Maitzen, H. M.

Subjects
Astrophysics
Abstract

We present results of spectroscopic observations of selected stars in the southern open cluster NGC 6134. We have determined the rotational velocities of the six known Delta Scuti Stars in NGC 6134 as well as several other non-variable stars with similar colour temperature in order to investigate if v sin i and variability is somehow connected: we find no such correlation. We also compare the distribution of v sin i of Delta Scuti Stars and non-variable stars with four other well-studied open clusters to look for any systematic behaviour, but we find no conclusive evidence for v sin i and variability to be connected. We have also used the spectra to carry out an abundance analysis of the Delta Scuti Stars in NGC 6134 to confirm the high metal content of the cluster. We find [Fe/H] = +0.38 +/- 0.05 which is in agreement with the result obtained from Stromgren photometry. We also present Delta-a photometry of the cluster, but we find no chemical peculiar stars based on this index., Comment: 12 pages, 7 figures

Published
2002
Full Text
View/download PDF

29. Abundance of fin whales in West Greenland in 2007

Author

Heide-Jørgensen, M. P., Laidre, K. L., Simon, M., Burt, M. L., David Borchers, and Rasmussen, M.

Subjects
Animal Science and Zoology, Aquatic Science, Ecology, Evolution, Behavior and Systematics
Abstract

An aerial line transect survey of fin whales (Balaenoptera physalus) conducted off West Greenland in 2007 was used to estimate the current abundance of fin whales on the summer feeding ground. A total of 24 sightings of fin whale groups were collected during 8,632km of survey effort in sea states

Published
2023

30. Drug survival of biologic therapies for palmoplantar pustulosis: A nationwide study.

Author

Bertelsen, T., Egeberg, A., Skov, L., Rasmussen, M., Bryld, L., Funding, A., Ajgeiy, K., and Thein, D.

Subjects
BIOTHERAPY, SURVIVAL rate, DRUGS, QUALITY of life, DESCRIPTIVE statistics
Abstract

Background: Biological therapies have established efficacy in psoriasis vulgaris. However, palmoplantar pustulosis (PPP) has proven difficult to treat, and data on drug survival in these patients remain scarce. Objective: To investigate drug survival of biological treatments in a nationwide cohort of patients with PPP. Methods: We included all patients treated for PPP with a biologic from a prospective Danish nationwide registry between 2007 and 2019. Descriptive statistics were reported. Drug survival was calculated for all patients and specified for the most frequently used biologics. Drug survival was reported as median time to discontinuation. Kaplan–Meier plots were used to visualize drug survival. Trajectories of Dermatology Life Quality Index (DLQI) scores were plotted by interpolating between the different visits with a dermatologist for each treatment course. Results: We identified 85 individual patients who received biological therapy for PPP across 194 treatment courses during follow‐up. Of the included treatment courses, 151 (77.8%) were discontinued. The most frequent cause of discontinuation was ineffective response to treatment (54.3%), while 18.5% of courses were discontinued due to adverse events. The median drug survival across all therapies for PPP was 9.3 (Inter quartile range (IQR), 3.9–25.6) months. Ustekinumab demonstrated the longest median time to discontinuation of 14.6 (IQR, 9.1–51.8) months. The proportion of bio‐naive patients in treatment at 12 months were according to drug 47.9% for adalimumab, 64.3% for ustekinumab and 40.0% for secukinumab. For bio‐experienced, it was 58.2% adalimumab, 54.5% for ustekinumab and 51.4% for secukinumab. Conclusions: The treatment of PPP poses significant challenges, with limited drug survival observed across all therapies regardless of prior experience with biologics. Ustekinumab demonstrated the longest median drug survival. Notably, patients discontinuing therapy due to inefficacy exhibited higher DLQI scores, highlighting the importance of personalized treatment selection and timely consideration of therapy changes when inefficacy is established. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Effects of phenylephrine on systemic and cerebral circulations in humans: a systematic review with mechanistic explanations.

Author

Meng, L., Sun, Y., Zhao, X., Meng, D. M., Liu, Z., Adams, D. C., McDonagh, D. L., and Rasmussen, M.

Subjects
CEREBRAL circulation, PHENYLEPHRINE, CARDIAC output, OXYGEN saturation, BOLUS drug administration
Abstract

Summary: We conducted a systematic review of the literature reporting phenylephrine‐induced changes in blood pressure, cardiac output, cerebral blood flow and cerebral tissue oxygen saturation as measured by near‐infrared spectroscopy in humans. We used the proportion change of the group mean values reported by the original studies in our analysis. Phenylephrine elevates blood pressure whilst concurrently inducing a reduction in cardiac output. Furthermore, despite increasing cerebral blood flow, it decreases cerebral tissue oxygen saturation. The extent of phenylephrine's influence on cardiac output (r = ‐0.54 and p = 0.09 in awake humans; r = ‐0.55 and p = 0.007 in anaesthetised humans), cerebral blood flow (r = 0.65 and p = 0.002 in awake humans; r = 0.80 and p = 0.003 in anaesthetised humans) and cerebral tissue oxygen saturation (r = ‐0.72 and p = 0.03 in awake humans; r = ‐0.24 and p = 0.48 in anaesthetised humans) appears closely linked to the magnitude of phenylephrine‐induced blood pressure changes. When comparing the effects of phenylephrine in awake and anaesthetised humans, we found no evidence of a significant difference in cardiac output, cerebral blood flow or cerebral tissue oxygen saturation. There was also no evidence of a significant difference in effect on systemic and cerebral circulations whether phenylephrine was given by bolus or infusion. We explore the underlying mechanisms driving the phenylephrine‐induced cardiac output reduction, cerebral blood flow increase and cerebral tissue oxygen saturation decrease. Individualised treatment approaches, close monitoring and consideration of potential risks and benefits remain vital to the safe and effective use of phenylephrine in acute care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Rehabilitation and outcomes after complicated vs uncomplicated mild TBI: results from the CENTER-TBI study

Author

Howe, E, Zeldovich, M, Andelic, N, von Steinbuechel, N, Fure, S, Borgen, I, Forslund, M, Hellstrom, T, Soberg, H, Sveen, U, Rasmussen, M, Kleffelgaard, I, Tverdal, C, Helseth, E, Lovstad, M, Lu, J, Arango-Lasprilla, J, Tenovuo, O, Azouvi, P, Dawes, H, Roe, C, Akerlund, C, Amrein, K, Andreassen, L, Anke, A, Antoni, A, Audibert, G, Azzolini, M, Bartels, R, Barzo, P, Beauvais, R, Beer, R, Bellander, B, Belli, A, Benali, H, Berardino, M, Beretta, L, Blaabjerg, M, Bragge, P, Brazinova, A, Brinck, V, Brooker, J, Brorsson, C, Buki, A, Bullinger, M, Cabeleira, M, Caccioppola, A, Calappi, E, Calvi, M, Cameron, P, Carbayo Lozano, G, Carbonara, M, Cavallo, S, Chevallard, G, Chieregato, A, Citerio, G, Clusmann, H, Coburn, M, Coles, J, Cooper, J, Correia, M, Covic, A, Curry, N, Czeiter, E, Czosnyka, M, Dahyot-Fizelier, C, Dark, P, De Keyser, V, Degos, V, Dellacorte, F, Denboogert, H, Depreitere, B, Dilvesi, D, Dixit, A, Donoghue, E, Dreier, J, Duliere, G, Ercole, A, Esser, P, Ezer, E, Fabricius, M, Feigin, V, Foks, K, Frisvold, S, Furmanov, A, Gagliardo, P, Galanaud, D, Gantner, D, Gao, G, George, P, Ghuysen, A, Giga, L, Glocker, B, Golubovic, J, Gomez, P, Gratz, J, Gravesteijn, B, Grossi, F, Gruen, R, Gupta, D, Haagsma, J, Haitsma, I, Helbok, R, Horton, L, Huijben, J, Hutchinson, P, Jacobs, B, Jankowski, S, Jarrett, M, Jiang, J, Johnson, F, Jones, K, Karan, M, Kolias, A, Kompanje, E, Kondziella, D, Kornaropoulos, E, Koskinen, L, Kovacs, N, Kowark, A, Lagares, A, Lanyon, L, Laureys, S, Lecky, F, Ledoux, D, Lefering, R, Legrand, V, Lejeune, A, Levi, L, Lightfoot, R, Lingsma, H, Maas, A, Castano-Leon, A, Maegele, M, Majdan, M, Manara, A, Manley, G, Martino, C, Marechal, H, Mattern, J, Mcmahon, C, Melegh, B, Menon, D, Menovsky, T, Mikolic, A, Misset, B, Muraleedharan, V, Murray, L, Negru, A, Nelson, D, Newcombe, V, Nieboer, D, Nyiradi, J, Olubukola, O, Oresic, M, Ortolano, F, Palotie, A, Parizel, P, Payen, J, Perera, N, Perlbarg, V, Persona, P, Peul, W, Piippo-Karjalainen, A, Pirinen, M, Pisica, D, Ples, H, Polinder, S, Pomposo, I, Posti, J, Puybasset, L, Radoi, A, Ragauskas, A, Raj, R, Rambadagalla, M, Helmrich, I, Rhodes, J, Richardson, S, Richter, S, Ripatti, S, Rocka, S, Roise, O, Rosand, J, Rosenfeld, J, Rosenlund, C, Rosenthal, G, Rossaint, R, Rossi, S, Rueckert, D, Rusnak, M, Sahuquillo, J, Sakowitz, O, Sanchez-Porras, R, Sandor, J, Schafer, N, Schmidt, S, Schoechl, H, Schoonman, G, Schou, R, Schwendenwein, E, Sewalt, C, Singh, R, Skandsen, T, Smielewski, P, Sorinola, A, Stamatakis, E, Stanworth, S, Stevens, R, Stewart, W, Steyerberg, E, Stocchetti, N, Sundstrom, N, Takala, R, Tamas, V, Tamosuitis, T, Taylor, M, Ao, B, Theadom, A, Thomas, M, Tibboel, D, Timmers, M, Tolias, C, Trapani, T, Tudora, C, Unterberg, A, Vajkoczy, P, Vallance, S, Valeinis, E, Vamos, Z, van der Jagt, M, Van der Steen, G, van der Naalt, J, van Dijck, J, van Erp, I, van Essen, T, Van Hecke, W, van Heugten, C, Van Praag, D, van Veen, E, Vyvere, T, van Wijk, R, Vargiolu, A, Vega, E, Velt, K, Verheyden, J, Vespa, P, Vik, A, Vilcinis, R, Volovici, V, von Steinbuchel, N, Voormolen, D, Vulekovic, P, Wang, K, Whitehouse, D, Wiegers, E, Williams, G, Wilson, L, Winzeck, S, Wolf, S, Yang, Z, Ylen, P, Younsi, A, Zeiler, F, Zelinkova, V, Ziverte, A, Zoerle, T, Howe E. I., Zeldovich M., Andelic N., von Steinbuechel N., Fure S. C. R., Borgen I. M. H., Forslund M. V., Hellstrom T., Soberg H. L., Sveen U., Rasmussen M., Kleffelgaard I., Tverdal C., Helseth E., Lovstad M., Lu J., Arango-Lasprilla J. C., Tenovuo O., Azouvi P., Dawes H., Roe C., Akerlund C., Amrein K., Andreassen L., Anke A., Antoni A., Audibert G., Azzolini M. L., Bartels R., Barzo P., Beauvais R., Beer R., Bellander B. -M., Belli A., Benali H., Berardino M., Beretta L., Blaabjerg M., Bragge P., Brazinova A., Brinck V., Brooker J., Brorsson C., Buki A., Bullinger M., Cabeleira M., Caccioppola A., Calappi E., Calvi M. R., Cameron P., Carbayo Lozano G., Carbonara M., Cavallo S., Chevallard G., Chieregato A., Citerio G., Clusmann H., Coburn M., Coles J., Cooper J. D., Correia M., Covic A., Curry N., Czeiter E., Czosnyka M., Dahyot-Fizelier C., Dark P., De Keyser V., Degos V., DellaCorte F., denBoogert H., Depreitere B., Dilvesi D., Dixit A., Donoghue E., Dreier J., Duliere G. -L., Ercole A., Esser P., Ezer E., Fabricius M., Feigin V. L., Foks K., Frisvold S., Furmanov A., Gagliardo P., Galanaud D., Gantner D., Gao G., George P., Ghuysen A., Giga L., Glocker B., Golubovic J., Gomez P. A., Gratz J., Gravesteijn B., Grossi F., Gruen R. L., Gupta D., Haagsma J. A., Haitsma I., Helbok R., Horton L., Huijben J., Hutchinson P. J., Jacobs B., Jankowski S., Jarrett M., Jiang J. -Y., Johnson F., Jones K., Karan M., Kolias A. G., Kompanje E., Kondziella D., Kornaropoulos E., Koskinen L. -O., Kovacs N., Kowark A., Lagares A., Lanyon L., Laureys S., Lecky F., Ledoux D., Lefering R., Legrand V., Lejeune A., Levi L., Lightfoot R., Lingsma H., Maas A. I. R., Castano-Leon A. M., Maegele M., Majdan M., Manara A., Manley G., Martino C., Marechal H., Mattern J., McMahon C., Melegh B., Menon D., Menovsky T., Mikolic A., Misset B., Muraleedharan V., Murray L., Negru A., Nelson D., Newcombe V., Nieboer D., Nyiradi J., Olubukola O., Oresic M., Ortolano F., Palotie A., Parizel P. M., Payen J. -F., Perera N., Perlbarg V., Persona P., Peul W., Piippo-Karjalainen A., Pirinen M., Pisica D., Ples H., Polinder S., Pomposo I., Posti J. P., Puybasset L., Radoi A., Ragauskas A., Raj R., Rambadagalla M., Helmrich I. R., Rhodes J., Richardson S., Richter S., Ripatti S., Rocka S., Roise O., Rosand J., Rosenfeld J. V., Rosenlund C., Rosenthal G., Rossaint R., Rossi S., Rueckert D., Rusnak M., Sahuquillo J., Sakowitz O., Sanchez-Porras R., Sandor J., Schafer N., Schmidt S., Schoechl H., Schoonman G., Schou R. F., Schwendenwein E., Sewalt C., Singh R. D., Skandsen T., Smielewski P., Sorinola A., Stamatakis E., Stanworth S., Stevens R., Stewart W., Steyerberg E. W., Stocchetti N., Sundstrom N., Takala R., Tamas V., Tamosuitis T., Taylor M. S., Ao B. T., Theadom A., Thomas M., Tibboel D., Timmers M., Tolias C., Trapani T., Tudora C. M., Unterberg A., Vajkoczy P., Vallance S., Valeinis E., Vamos Z., van der Jagt M., Van der Steen G., van der Naalt J., van Dijck J. T. J. M., van Erp I. A. M., van Essen T. A., Van Hecke W., van Heugten C., Van Praag D., van Veen E., Vyvere T. V., van Wijk R. P. J., Vargiolu A., Vega E., Velt K., Verheyden J., Vespa P. M., Vik A., Vilcinis R., Volovici V., von Steinbuchel N., Voormolen D., Vulekovic P., Wang K. K. W., Whitehouse D., Wiegers E., Williams G., Wilson L., Winzeck S., Wolf S., Yang Z., Ylen P., Younsi A., Zeiler F. A., Zelinkova V., Ziverte A., Zoerle T., Howe, E, Zeldovich, M, Andelic, N, von Steinbuechel, N, Fure, S, Borgen, I, Forslund, M, Hellstrom, T, Soberg, H, Sveen, U, Rasmussen, M, Kleffelgaard, I, Tverdal, C, Helseth, E, Lovstad, M, Lu, J, Arango-Lasprilla, J, Tenovuo, O, Azouvi, P, Dawes, H, Roe, C, Akerlund, C, Amrein, K, Andreassen, L, Anke, A, Antoni, A, Audibert, G, Azzolini, M, Bartels, R, Barzo, P, Beauvais, R, Beer, R, Bellander, B, Belli, A, Benali, H, Berardino, M, Beretta, L, Blaabjerg, M, Bragge, P, Brazinova, A, Brinck, V, Brooker, J, Brorsson, C, Buki, A, Bullinger, M, Cabeleira, M, Caccioppola, A, Calappi, E, Calvi, M, Cameron, P, Carbayo Lozano, G, Carbonara, M, Cavallo, S, Chevallard, G, Chieregato, A, Citerio, G, Clusmann, H, Coburn, M, Coles, J, Cooper, J, Correia, M, Covic, A, Curry, N, Czeiter, E, Czosnyka, M, Dahyot-Fizelier, C, Dark, P, De Keyser, V, Degos, V, Dellacorte, F, Denboogert, H, Depreitere, B, Dilvesi, D, Dixit, A, Donoghue, E, Dreier, J, Duliere, G, Ercole, A, Esser, P, Ezer, E, Fabricius, M, Feigin, V, Foks, K, Frisvold, S, Furmanov, A, Gagliardo, P, Galanaud, D, Gantner, D, Gao, G, George, P, Ghuysen, A, Giga, L, Glocker, B, Golubovic, J, Gomez, P, Gratz, J, Gravesteijn, B, Grossi, F, Gruen, R, Gupta, D, Haagsma, J, Haitsma, I, Helbok, R, Horton, L, Huijben, J, Hutchinson, P, Jacobs, B, Jankowski, S, Jarrett, M, Jiang, J, Johnson, F, Jones, K, Karan, M, Kolias, A, Kompanje, E, Kondziella, D, Kornaropoulos, E, Koskinen, L, Kovacs, N, Kowark, A, Lagares, A, Lanyon, L, Laureys, S, Lecky, F, Ledoux, D, Lefering, R, Legrand, V, Lejeune, A, Levi, L, Lightfoot, R, Lingsma, H, Maas, A, Castano-Leon, A, Maegele, M, Majdan, M, Manara, A, Manley, G, Martino, C, Marechal, H, Mattern, J, Mcmahon, C, Melegh, B, Menon, D, Menovsky, T, Mikolic, A, Misset, B, Muraleedharan, V, Murray, L, Negru, A, Nelson, D, Newcombe, V, Nieboer, D, Nyiradi, J, Olubukola, O, Oresic, M, Ortolano, F, Palotie, A, Parizel, P, Payen, J, Perera, N, Perlbarg, V, Persona, P, Peul, W, Piippo-Karjalainen, A, Pirinen, M, Pisica, D, Ples, H, Polinder, S, Pomposo, I, Posti, J, Puybasset, L, Radoi, A, Ragauskas, A, Raj, R, Rambadagalla, M, Helmrich, I, Rhodes, J, Richardson, S, Richter, S, Ripatti, S, Rocka, S, Roise, O, Rosand, J, Rosenfeld, J, Rosenlund, C, Rosenthal, G, Rossaint, R, Rossi, S, Rueckert, D, Rusnak, M, Sahuquillo, J, Sakowitz, O, Sanchez-Porras, R, Sandor, J, Schafer, N, Schmidt, S, Schoechl, H, Schoonman, G, Schou, R, Schwendenwein, E, Sewalt, C, Singh, R, Skandsen, T, Smielewski, P, Sorinola, A, Stamatakis, E, Stanworth, S, Stevens, R, Stewart, W, Steyerberg, E, Stocchetti, N, Sundstrom, N, Takala, R, Tamas, V, Tamosuitis, T, Taylor, M, Ao, B, Theadom, A, Thomas, M, Tibboel, D, Timmers, M, Tolias, C, Trapani, T, Tudora, C, Unterberg, A, Vajkoczy, P, Vallance, S, Valeinis, E, Vamos, Z, van der Jagt, M, Van der Steen, G, van der Naalt, J, van Dijck, J, van Erp, I, van Essen, T, Van Hecke, W, van Heugten, C, Van Praag, D, van Veen, E, Vyvere, T, van Wijk, R, Vargiolu, A, Vega, E, Velt, K, Verheyden, J, Vespa, P, Vik, A, Vilcinis, R, Volovici, V, von Steinbuchel, N, Voormolen, D, Vulekovic, P, Wang, K, Whitehouse, D, Wiegers, E, Williams, G, Wilson, L, Winzeck, S, Wolf, S, Yang, Z, Ylen, P, Younsi, A, Zeiler, F, Zelinkova, V, Ziverte, A, Zoerle, T, Howe E. I., Zeldovich M., Andelic N., von Steinbuechel N., Fure S. C. R., Borgen I. M. H., Forslund M. V., Hellstrom T., Soberg H. L., Sveen U., Rasmussen M., Kleffelgaard I., Tverdal C., Helseth E., Lovstad M., Lu J., Arango-Lasprilla J. C., Tenovuo O., Azouvi P., Dawes H., Roe C., Akerlund C., Amrein K., Andreassen L., Anke A., Antoni A., Audibert G., Azzolini M. L., Bartels R., Barzo P., Beauvais R., Beer R., Bellander B. -M., Belli A., Benali H., Berardino M., Beretta L., Blaabjerg M., Bragge P., Brazinova A., Brinck V., Brooker J., Brorsson C., Buki A., Bullinger M., Cabeleira M., Caccioppola A., Calappi E., Calvi M. R., Cameron P., Carbayo Lozano G., Carbonara M., Cavallo S., Chevallard G., Chieregato A., Citerio G., Clusmann H., Coburn M., Coles J., Cooper J. D., Correia M., Covic A., Curry N., Czeiter E., Czosnyka M., Dahyot-Fizelier C., Dark P., De Keyser V., Degos V., DellaCorte F., denBoogert H., Depreitere B., Dilvesi D., Dixit A., Donoghue E., Dreier J., Duliere G. -L., Ercole A., Esser P., Ezer E., Fabricius M., Feigin V. L., Foks K., Frisvold S., Furmanov A., Gagliardo P., Galanaud D., Gantner D., Gao G., George P., Ghuysen A., Giga L., Glocker B., Golubovic J., Gomez P. A., Gratz J., Gravesteijn B., Grossi F., Gruen R. L., Gupta D., Haagsma J. A., Haitsma I., Helbok R., Horton L., Huijben J., Hutchinson P. J., Jacobs B., Jankowski S., Jarrett M., Jiang J. -Y., Johnson F., Jones K., Karan M., Kolias A. G., Kompanje E., Kondziella D., Kornaropoulos E., Koskinen L. -O., Kovacs N., Kowark A., Lagares A., Lanyon L., Laureys S., Lecky F., Ledoux D., Lefering R., Legrand V., Lejeune A., Levi L., Lightfoot R., Lingsma H., Maas A. I. R., Castano-Leon A. M., Maegele M., Majdan M., Manara A., Manley G., Martino C., Marechal H., Mattern J., McMahon C., Melegh B., Menon D., Menovsky T., Mikolic A., Misset B., Muraleedharan V., Murray L., Negru A., Nelson D., Newcombe V., Nieboer D., Nyiradi J., Olubukola O., Oresic M., Ortolano F., Palotie A., Parizel P. M., Payen J. -F., Perera N., Perlbarg V., Persona P., Peul W., Piippo-Karjalainen A., Pirinen M., Pisica D., Ples H., Polinder S., Pomposo I., Posti J. P., Puybasset L., Radoi A., Ragauskas A., Raj R., Rambadagalla M., Helmrich I. R., Rhodes J., Richardson S., Richter S., Ripatti S., Rocka S., Roise O., Rosand J., Rosenfeld J. V., Rosenlund C., Rosenthal G., Rossaint R., Rossi S., Rueckert D., Rusnak M., Sahuquillo J., Sakowitz O., Sanchez-Porras R., Sandor J., Schafer N., Schmidt S., Schoechl H., Schoonman G., Schou R. F., Schwendenwein E., Sewalt C., Singh R. D., Skandsen T., Smielewski P., Sorinola A., Stamatakis E., Stanworth S., Stevens R., Stewart W., Steyerberg E. W., Stocchetti N., Sundstrom N., Takala R., Tamas V., Tamosuitis T., Taylor M. S., Ao B. T., Theadom A., Thomas M., Tibboel D., Timmers M., Tolias C., Trapani T., Tudora C. M., Unterberg A., Vajkoczy P., Vallance S., Valeinis E., Vamos Z., van der Jagt M., Van der Steen G., van der Naalt J., van Dijck J. T. J. M., van Erp I. A. M., van Essen T. A., Van Hecke W., van Heugten C., Van Praag D., van Veen E., Vyvere T. V., van Wijk R. P. J., Vargiolu A., Vega E., Velt K., Verheyden J., Vespa P. M., Vik A., Vilcinis R., Volovici V., von Steinbuchel N., Voormolen D., Vulekovic P., Wang K. K. W., Whitehouse D., Wiegers E., Williams G., Wilson L., Winzeck S., Wolf S., Yang Z., Ylen P., Younsi A., Zeiler F. A., Zelinkova V., Ziverte A., and Zoerle T.

Abstract

Background: Despite existing guidelines for managing mild traumatic brain injury (mTBI), evidence-based treatments are still scarce and large-scale studies on the provision and impact of specific rehabilitation services are needed. This study aimed to describe the provision of rehabilitation to patients after complicated and uncomplicated mTBI and investigate factors associated with functional outcome, symptom burden, and TBI-specific health-related quality of life (HRQOL) up to six months after injury. Methods: Patients (n = 1379) with mTBI from the Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) study who reported whether they received rehabilitation services during the first six months post-injury and who participated in outcome assessments were included. Functional outcome was measured with the Glasgow Outcome Scale – Extended (GOSE), symptom burden with the Rivermead Post Concussion Symptoms Questionnaire (RPQ), and HRQOL with the Quality of Life after Brain Injury – Overall Scale (QOLIBRI-OS). We examined whether transition of care (TOC) pathways, receiving rehabilitation services, sociodemographic (incl. geographic), premorbid, and injury-related factors were associated with outcomes using regression models. For easy comparison, we estimated ordinal regression models for all outcomes where the scores were classified based on quantiles. Results: Overall, 43% of patients with complicated and 20% with uncomplicated mTBI reported receiving rehabilitation services, primarily in physical and cognitive domains. Patients with complicated mTBI had lower functional level, higher symptom burden, and lower HRQOL compared to uncomplicated mTBI. Rehabilitation services at three or six months and a higher number of TOC were associated with unfavorable outcomes in all models, in addition to pre-morbid psychiatric problems. Being male and having more than 13 years of education was associated with more favorable outcomes. Sustaining major trauma w

Published
2022

34. Grey-box modeling for hot-spot temperature prediction of oil-immersed transformers in power distribution networks

Author

Blomgren, E. M.V., D'Ettorre, F., Samuelsson, O., Banaei, M., Ebrahimy, R., Rasmussen, M. E., Nielsen, N. H., Larsen, A. R., Madsen, H., Blomgren, E. M.V., D'Ettorre, F., Samuelsson, O., Banaei, M., Ebrahimy, R., Rasmussen, M. E., Nielsen, N. H., Larsen, A. R., and Madsen, H.

Abstract

Power transformers are one of the most costly assets in power grids. Due to increasing electricity demand and levels of distributed generation, they are more and more often loaded above their rated limits. Transformer ratings are traditionally set as static limits, set in a controlled environment with conservative margins. Through dynamic transformer rating, the rating is instead adapted to the actual working conditions of the transformers. This can help distribution system operators (DSOs) to unlock unused capacity and postpone costly grid investments. To this end, real-time information of the transformer operating conditions, and in particular of its hot-spot and oil temperature, is required. This work proposes a grey-box model that can be used for online estimation and forecasting of the transformer temperature. It relies on a limited set of non-intrusive measurements and was developed using experimental data from a DSO in Jutland, Denmark. The thermal model has proven to be able to predict the temperature of the transformers with a high accuracy and low computational time, which is particularly relevant for online applications. With a six-hour prediction horizon the mean average error was 0.4–0.6 °C. By choosing a stochastic data-driven modeling approach we can also provide prediction intervals and account for the uncertainty.

Published
2023

35. OP11.02:Pregnancy outcome of quadruplet pregnancies: a national Danish cohort study between 2008–2018

Author

Rasmussen, M. K., Kristensen, S. E., Ekelund, C. K., Sandager, P., Joergensen, F. S., Hoseth, E., Sperling, L., Zingenberg, H. J., Hjortshøj, T. D., Gadsbøll, K. Mørch, Wright, A., Wright, D., Mclennan, A., Sundberg, K., Petersen, O. B., Rasmussen, M. K., Kristensen, S. E., Ekelund, C. K., Sandager, P., Joergensen, F. S., Hoseth, E., Sperling, L., Zingenberg, H. J., Hjortshøj, T. D., Gadsbøll, K. Mørch, Wright, A., Wright, D., Mclennan, A., Sundberg, K., and Petersen, O. B.

Published
2023

43. DOP19 Incidence and initial disease presentation of inflammatory bowel diseases in Denmark: findings from a Copenhagen IBD Inception Cohort Study (IBD Prognosis Study)

Author

Attauabi, M, primary, Madsen, G R, additional, Wewer, A V, additional, Bendtsen, F, additional, Jakobsen, C, additional, Dorn-Rasmussen, M, additional, Malham, M, additional, Theede, K, additional, Bjerrum, J T, additional, Boysen, T, additional, Seidelin, J B, additional, and Burisch, J, additional

Published
2023
Full Text
View/download PDF

44. A traumatic spinal cord injury critical care porcine model

Author

Thygesen, M., primary, Entezari, S., additional, Houlind, N., additional, Nielsen, T.H., additional, Olesen, N.Ø., additional, Skov, M., additional, Nielsen, T.D., additional, Tankisi, A., additional, Rasmussen, M., additional, Einarsson, H.B., additional, Agger, P., additional, Dariusz, O., additional, Dyrskog, S.E., additional, Thorup, L., additional, Pedersen, M., additional, and Rasmussen, M.M., additional

Published
2023
Full Text
View/download PDF

48. Briefings

Author

Long, J. A., Rasmussen, M., Savage, P. S., Liu, N., and Feldman, P. D.

Published
2015

49. Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial

Author

Jensen, Jens-Ulrik S., Itenov, Theis S., Thormar, Katrin M., Hein, Lars, Mohr, Thomas T., Andersen, Mads H., Løken, Jesper, Tousi, Hamid, Lundgren, Bettina, Boesen, Hans Christian, Johansen, Maria E., Ostrowski, Sisse R., Johansson, Pär I., Grarup, Jesper, Vestbo, Jørgen, Lundgren, Jens D., Steensen, M., Thornberg, K., Bestle, M., Strange, D., Lauritsen, A. Ø., Søe-Jensen, P., Reiter, N., Drenck, N. E., Fjeldborg, P., Fox, Z., Kjær, J., Kristensen, D., Rasmussen, M. B., Hallas, C. S.v., Zacho, M., Østergaard, C., Petersen, P. L., Hougaard, S., Mantoni, T., Nebrich, L., Bendtsen, A., Andersen, L. H., Bærentzen, F., Eversbusch, Andreas, Bømler, B., Martusevicius, R., Nielsen, T., Bådstøløkken, P. M., Grevstad, U., Hallas, P., Lindhardt, A., Galle, T., Graeser, K., Hohwu-Christensen, E., Gregersen, P., Pedersen, L. M., Rye, I., Cordtz, J., Madsen, K. R., Kirkegaard, P. R. C., Findsen, L., Nielsen, L. H., Pedersen, D. H., Andersen, J. H., Albrechtsen, C., Jacobsen, A., Jansen, T., Jensen, A. G., Jørgensen, H. H., Vazin, M., Lipsius, L., Skielboe, M., Thage, B., Thoft, C., Uldbjerg, M., Anderlo, E., Engsig, M., Hani, F., Jacobsen, R. B., Mulla, L., Skram, U., Waldau, T., Faber, T., Andersen, B., Gillesberg, I., Christensen, A., Hartmann, C., Albret, R., Dinesen, D. S., Gani, K., Ibsen, M., Petersen, J. A., Carl, P., Gade, E., Solevad, D., Heiring, C., Jørgensen, M., Ekelund, K., Afshari, A., Hammer, N., Bitsch, M., Hansen, J. S., Wamberg, C., Clausen, T. D., Winkel, R., Huusom, J., Buck, D. L., Grevstad, U., Lenz, K., Mellado, P., Karacan, H., Hidestål, J., Høgagard, J., Højbjerg, J., Højlund, J., Hestad, S., Østergaard, M., Wesche, N., Nielsen, S. A., Christensen, H., Blom, H., Jensen, C. H., Nielsen, K., Holler, N. G., Rossau, C. D., Glæemose, M., Wranér, M. B., Thomsen, C. B., Rasmussen, B., Lund-Rasmussen, C., Bech, B., Bjerregaard, K., Spliid, L., Nielsen, L. L. W., Larsen, K. M., Goldinger, M., Illum, D., Jessen, C., Christiansen, A., Berg, A., Elkmann, T., Pedersen, J. A. K., Simonsen, M., Joensen†, H., Alstrøm, H., Svane, C., Engquist, A., and For The Procalcitonin And Survival Study (PASS) Group

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results